The Mexican pharmaceutical Landsteiner Scientific interested in the “Sputnik-V” vaccine
Russia’s sovereign wealth fund confirmed on Wednesday that signed an agreement to export 32 million doses of its “Sputnik-V” vaccine against the coronavirus to the Mexican pharmaceutical company Landsteiner Scientific.
Delivery of the vaccine to Mexico will begin in November, provided it gets approval from Mexican regulators, Russia’s Direct Investment Fund (RDIF) said in a statement.
The scientific journal The Lancet published last Friday a preliminary study on a Russian vaccine that showed that it allows to develop an immune response without serious undesirable effects.
According to The Lancet the vaccine, called “Sputnik V” and announced with great fanfare by the Kremlin, It was applied to 76 volunteers and generated “neutralizing antibodies” to covid-19. However, the article indicates that “large-scale trials” are still needed.
This will be the goal of the phase 3 trial, which will include 40,000 participants, they explained..
The “Sputnik V” actually consists of two vaccines, administered in injections each three weeks apart, detailed the study published in The Lancet.
It is a “viral vector” vaccine: it uses two human adenoviruses – a very common family of viruses, responsible above all for colds – that are transformed to add the SARS-CoV-2 virus, which causes covid-19.
When the modified adenovirus enters the cells of the vaccinated person, it makes a typical SARS-CoV-2 protein, thus teaching their immune system to recognize and fight it, explains the lead author of the article, Denis Logounov, from the Gamaleïa Institute.
The publication is based on two small studies conducted among a total of 76 adult volunteers, between 18 and 60 years old, in good health. They were carried out between June 18 and August 3 by researchers from the Russian ministries of Health and Defense and funded by the former.
Both concluded that neither of the two components of the vaccine caused “serious undesirable effects” and that its successive administration “generated the production of antibodies” in all participants, including “neutralizing antibodies” to covid-19.
Copyright law strictly forbids copying all or part of Excelsior’s materials without first obtaining written permission and without including the link to the original text.